TLSITriSalus Life Sciences Inc
TLSI
TriSalus Life Sciences Inc297
Mkt Cap
$240.93MVolume
396,264.0052W High
$7.9552W Low
$3.42PE Ratio
-2.15TLSI Fundamentals
Price
$3.93Prev Close
$3.86Open
$3.8750D MA
$4.94Beta
0.50Avg. Volume
177,030.04EPS (Annual)
-$1.84P/B
-5.80Rev/Employee
$442,656.86$278.53
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells 4,358 Shares of Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive...
MarketBeat·15h ago
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 4,358 shares of the firm's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.13, for a total value of $17,998.54. Following the transaction, the chief executive officer...
MarketBeat·1d ago
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela sold 15,944 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total value of $61,384.40. Following the sale, the chief executive officer owned 752,987...
MarketBeat·1d ago
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·4d ago
Research Analysts Issue Forecasts for TLSI Q1 Earnings
TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Northland Securities issued their Q1 2026 earnings per share estimates for TriSalus Life Sciences in a research report issued on...
MarketBeat·13d ago
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded TriSalus Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·15d ago
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price
Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Friday...
MarketBeat·15d ago
TriSalus Life Sciences Q4 Earnings Call Highlights
TriSalus Life Sciences (NASDAQ:TLSI) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by growth in its TriNav product suite and broader adoption of...
MarketBeat·16d ago
TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·16d ago
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...
Business Wire·16d ago
<
1
2
...
>